Kamada Issues 2024 CEO Letter to Shareholders
The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.
- The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field.
- Looking ahead, we expect the momentum from 2023 to extend throughout 2024, with profitability to be further increased as compared to last year.
- These significant catalysts are propelling our continued annual double-digit profitable growth with substantial upside potential and limited downside risk.
- On behalf of the entire Kamada team, we look forward to continuing to support patients and clinicians with the important lifesaving products that we develop, manufacture, and commercialize.